We mourn Sir Peter Morris’ passing. He was an inspiration and support to many of us.
In memoriam: Sir Peter Morris (1934 – 2022)

We mourn Sir Peter Morris’ passing. He was an inspiration and support to many of us.
Our new policy report, ‘Tackling Inequalities in Organ Transplantation: A Pathway Forward’ sets out 5 five core actions that European stakeholders and ESOT must take to tackle disparities across Europe.
ESOT is strongly committed to principles of equity, diversity and inclusion and strives to promote such values through its education programme. Members of traditionally underrepresented and marginalized groups are particularly encouraged to apply both as mentors and as mentees.
We are delighted to announce the ESOT Grants Programme for 2023!
All grants recipients are required to be ESOT members in good standing with up-to-date fee payments.
Applications will open from 31 August 2022 and close on 31 October 2022.
• “This guide provides practical & technical guidance to ensure quality, safety & ethics in the practice of organ donation & transplantation”
We are pleased to announce our joint session with TAKEDA ‘A Level Playing Field for Transplant Patients‘ taking place at the European Health Forum in Gastein on Tuesday, 27 September 2022 | 17:00-18:30
💥 Attention transplant professionals!
The programme for the Educational Workshop on Guideline and Consensus Development at #ESOTTLJ is now live!
Find our more on this 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝘃𝗲 opportunity.
Keep up with ESOT – save the dates 🗓 06 July at 21:00 CEST #ESOTchat on Twitter >>> #ESOTTLJ with Annemarie Weissenbacher, Frank Dor and Umberto Cillo 🗓 07 July at 18:00 CEST Transplant International Webinar: Risk Stratification and Definition of Acute Rejection for Clinical Trials in Kidney Transplantation https://us02web.zoom.us/…/reg…/WN_eM3m814VRCm4FOLmevv6Dg 🗓 12 July at 18:00 CEST Transplant International
The Volume 35 | Issue 5 May 2022 of Transplant International is now out!
While the EU’s efforts have introduced significant improvements for the protection of the general population, the pandemic is far from over, and two major unmet needs disproportionately threaten immunocompromised patients.